THU0212 FIRST LINE TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: A MULTINATIONAL POPULATION-BASED COHORT FROM 14 REAL WORLD HEALTHCARE DATABASES AND 9 COUNTRIES - REALITY VERSUS GUIDELINES
Anthony G. Sena(Erasmus MC), Patrick Ryan(Johnson & Johnson (United States)), Elke Theander(Janssen (United States)), Antje Hottgenroth(Eli Lilly (Germany)), Katia Verhamme(Erasmus MC), Marcel de Wilde(Erasmus MC), Jennifer C. E. Lane(Nuffield Orthopaedic Centre), David Vizcaya(Bayer (Germany)), Daniel Prieto‐Alhambra(Nuffield Orthopaedic Centre), Nigel Hughes(Janssen (Belgium)), Sulev Reisberg(University of Tartu), Peter R. Rijnbeek(Erasmus MC), Raivo Kolde(University of Tartu), Sara Bruce Wirta(Novartis (Switzerland)), J. F. Golib-Dzib, Talita Duarte‐Salles(Erasmus MC), Denis Granados(Sanofi (France)), Carmen Olga Torre(IQVIA (United Kingdom)), Yesika Díaz(Institut Universitari d'Investigació en Atenció Primària Jordi Gol), Edward Burn(University of Oxford), Katerina Chatzidionysiou(Karolinska Institutet), Walid Fakhouri(Eli Lilly (United States)), Emily Brouwer(Janssen (United States))
Cited by 1
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
g:Profiler—a web server for functional interpretation of gene lists (2016 update)
|Nucleic Acids Research|2016|1.4k